HA-1 TCR-transduced virus-specific donor-derived T cells

HA-1 TCR-transduced virus-specific donor-derived T cells is an investigational gene-modified adoptive cell therapy developed by the Leiden University Medical Center (LUMC) for the treatment of high-risk leukemia in patients who have undergone allogeneic stem cell transplantation (allo-SCT). The therapy consists of donor-derived cytomegalovirus (CMV)- and/or Epstein-Barr virus (EBV)-specific T cells that are retrovirally transduced ex vivo with a T-cell receptor (TCR) specific for the minor histocompatibility antigen HA-1 (HA-1H) and expanded prior to infusion. By targeting HA-1, which is exclusively expressed on hematopoietic cells and presented by HLA-A*02:01, the therapy aims to induce a selective graft-versus-leukemia (GVL) effect without causing graft-versus-host disease (GVHD) in non-hematopoietic tissues. A Phase I/II clinical trial (EudraCT 2010-024625-20) was completed, demonstrating safety but limited clinical efficacy due to insufficient in vivo expansion, leading to the termination of further development of this specific strategy.

Other names

HA-1H TCR-transduced virus-specific T cellsHA1H TCR-transduced virus-specific T cellsHA 1H TCR-transduced virus-specific T cellsHA-1H TCR-redirected virus-specific T-cellsHA1H TCR-redirected virus-specific T-cellsHA 1H TCR-redirected virus-specific T-cellsHA-1 TCR-transduced virus-specific donor T cellsHA1 TCR-transduced virus-specific donor T cellsHA 1 TCR-transduced virus-specific donor T cells